Viatris had its Relative Strength (RS) Rating upgraded from 68 to 71 Thursday — a welcome improvement, but still below the 80 or better score you prefer to see.
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating of above 80 as they launch their biggest price moves. See if Viatris can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While the stock is not near a proper buy point right now, see if it goes on to form and break out from a proper chart pattern.
In terms of fundamentals, Viatris has posted rising EPS growth in each of the last two reports. Revenue gains have been less impressive, coming in at -5% in the latest report.
Viatris holds the No. 4 rank among its peers in the Medical-Generic Drugs industry group. Teva Pharmaceutical ADR is the top-ranked stock within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
